# Centre Hospitalier Universitaire de Besançon

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/centre-hospitalier-universitaire-de-besancon/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 44 |
| Citations | 773,170 |
| City | Besançon |
| Country | FR |
| Description | Centre Hospitalier Universitaire de Besançon is a research organisation in Besançon, FR. OpenAlex records 15,556 works and 773,170 citations for it. 3,385 researchers list it as their most recent affiliation. |
| Homepage | http://www.chu-besancon.fr |
| OpenAlex ID | https://openalex.org/I4210087978 |
| Region | Bourgogne |
| Researchers | 3,385 |
| ROR ID | https://ror.org/0084te143 |
| Type | healthcare |
| Wikidata ID | Q3145168 |
| Works | 15,556 |

## University papers

Showing 12 of 35.

- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis](https://scholariq.org/papers/2010-update-of-the-asas-eular-recommendations-for-the-management-of-ankylosing/)
- [Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-her2/)
- [Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-versus-active-surveillance-in-patients-with/)
- [Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study](https://scholariq.org/papers/tislelizumab-versus-chemotherapy-as-second-line-treatment-for-advanced-or/)
- [Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery](https://scholariq.org/papers/tranexamic-acid-for-the-prevention-of-blood-loss-after-cesarean-delivery-2/)
- [Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses](https://scholariq.org/papers/randomized-phase-iii-trial-of-dose-dense-methotrexate-vinblastine-doxorubicin/)
- [The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients](https://scholariq.org/papers/the-desir-cohort-a-10-year-follow-up-of-early-inflammatory-back-pain-in-france/)
- [Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial](https://scholariq.org/papers/adalimumab-in-patients-with-hand-osteoarthritis-refractory-to-analgesics-and/)
- [Prevention of spontaneous preterm birth: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF)](https://scholariq.org/papers/prevention-of-spontaneous-preterm-birth-guidelines-for-clinical-practice-from/)
- [Maternal outcomes and risk factors for COVID-19 severity among pregnant women](https://scholariq.org/papers/maternal-outcomes-and-risk-factors-for-covid-19-severity-among-pregnant-women/)
- [Anatomy and histology of apical support: a literature review concerning cardinal and uterosacral ligaments](https://scholariq.org/papers/anatomy-and-histology-of-apical-support-a-literature-review-concerning-cardinal/)

## University researchers

- [Nicolas Mottet](https://scholariq.org/researchers/nicolas-mottet/)
- [R. Ramanah](https://scholariq.org/researchers/r-ramanah/)
- [R. Maillet](https://scholariq.org/researchers/r-maillet/)

## University top topics

Showing 8 of 25.

- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Antibiotic Resistance in Bacteria](https://scholariq.org/topics/antibiotic-resistance-in-bacteria/)
- [Health, Medicine and Society](https://scholariq.org/topics/health-medicine-and-society/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.